Compare GT & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GT | PGEN |
|---|---|---|
| Founded | 1898 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2005 | 2013 |
| Metric | GT | PGEN |
|---|---|---|
| Price | $5.71 | $3.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $9.13 | $8.33 |
| AVG Volume (30 Days) | ★ 8.9M | 4.2M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,280,000,000.00 | $230,981,000.00 |
| Revenue This Year | N/A | $1,115.92 |
| Revenue Next Year | $3.06 | $81.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.43 | $1.38 |
| 52 Week High | $12.03 | $5.47 |
| Indicator | GT | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 34.06 | 36.15 |
| Support Level | $5.43 | $3.49 |
| Resistance Level | $6.26 | $3.64 |
| Average True Range (ATR) | 0.19 | 0.27 |
| MACD | 0.01 | -0.08 |
| Stochastic Oscillator | 27.71 | 7.39 |
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment. The company operates its business through three operating segments representing its regional tire businesses: Americas; Europe, the Middle East, and Africa (EMEA); and the Asia Pacific. The majority of its revenue is generated from the Americas business, which develops, manufactures, distributes, and sells tires and related products and services in North, Central, and South America, along with selling tires to various export markets, mainly through intersegment sales.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.